Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Clinical applications of a novel sustained-release injectable drug delivery system: DepoFoam (TM) technology
Autore:
Howell, SB;
Indirizzi:
Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA Univ Calif San Diego La Jolla CA USA 92093 pt Med, La Jolla, CA 92093 USA Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA Univ Calif San Diego La Jolla CA USA 92093 r Canc, La Jolla, CA 92093 USA
Titolo Testata:
CANCER JOURNAL
fascicolo: 3, volume: 7, anno: 2001,
pagine: 219 - 227
SICI:
1528-9117(200105/06)7:3<219:CAOANS>2.0.ZU;2-V
Fonte:
ISI
Lingua:
ENG
Soggetto:
RECOMBINANT ALPHA-INTERFERON; GLAUCOMA FILTERING SURGERY; EPITHELIAL OVARIAN-CANCER; SOFT-TISSUE INFECTION; MULTIVESICULAR LIPOSOMES; SLOW-RELEASE; CYTOSINE-ARABINOSIDE; CEREBROSPINAL-FLUID; PHASE-I; PROLIFERATIVE VITREORETINOPATHY;
Keywords:
chemotherapy; cytarabine; DepoFoam (TM); lymphomatous meningitis; leptomeningeal metastases; morphine; multivesicular liposomes; neoplastic meningitis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
64
Recensione:
Indirizzi per estratti:
Indirizzo: Howell, SB Univ Calif San Diego, Dept Med 0058, 9500 Gilman Dr, La Jolla, CA 92093 USA Univ Calif San Diego 9500 Gilman Dr La Jolla CA USA 92093 3 USA
Citazione:
S.B. Howell, "Clinical applications of a novel sustained-release injectable drug delivery system: DepoFoam (TM) technology", CANCER J, 7(3), 2001, pp. 219-227

Abstract

The therapeutic effectiveness of drugs is often limited by the inability to sustain therapeutic levels at the target site. Encapsulation of drugs in multivesicular lipid-based particles for sustained release is a novel approach to improving the pharmacokinetics of drug therapy. This paper reviews the preclinical and clinical literature on the applications and potential therapeutic benefits of DepoFoam(TM) technology, a novel sustained-release, injectable drug delivery system. DepoFoam(TM) formulations of drugs, including anticancer agents (cytarabine, methotrexate, bleomycin, recombinant interferon alfa, 5-fluorouridine-5'-monophosphate, and others), anti-infective agents (dideoxycytidine, 2'-norcyclic guanosine monophosphate, cidofovir, tobramycin, gentamicin, amikacin), analgesics (morphine, bupivacaine), and macromolecules (insulin, interleukin-2), delivered intrathecally, subcutaneously, intraperitoneally, or intralesionally, provide sustained therapeutic levels of drug at the intended target site and reduce systemic exposure and toxicity. Pharmacokinetic studies have demonstrated that DepoFoam(TM) particle encapsulation effectively extends the half- life of drugs, thus prolonging the duration of therapeutic drug concentrations in local tissues or in body spaces into which the encapsulated drug is injected. In the case of cell-cycle phase-specific chemotherapeutic agents, such formulations can improve efficacy and therapeutic ratio. DepoFoam(TM) is a prom ising drug delivery system for sustained release ofhydrophilic injectable drugs that has a wide range of potential applications in oncology, infectious disease, analgesia, and other therapeutic areas.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/03/20 alle ore 10:25:10